HUTCHMED is a biopharmaceutical company that researches, develops, manufactures, and sells pharmaceutical products. The company focuses on discovering and developing targeted therapies for oncology and immunological diseases. HUTCHMED's pipeline includes both small molecule and biologic drug candidates, with several products in clinical trials. The company has a global presence, with operations in China, the United States, and Europe. HUTCHMED is committed to improving patient outcomes through innovative drug development and commercialization.